High expression of miR-21 is not a predictor of poor prognosis in all patients with hepatocellular carcinoma

por Yi, Peng Sheng, Li, Jian Shui
Publicado 2018

Evolution and current status of the subclassification of intermediate hepatocellular carcinoma

por Yi, Peng-Sheng, Wang, Hong, Li, Jian-Shui
Publicado 2020

Should lymphadenectomy performed routinely in patients with primary intrahepatic cholangiocarcinoma undergoing curative hepatectomy? A retrospective cohort study with propensity-sc...

por Huang, Shan, Song, Jiu-Lin, Li, Bo, Yi, Peng-Sheng, Yang, Jian
Publicado 2023

The priority of liver resection compared with transarterial chemoembolization in hepatocellular carcinoma at BCLC B1 stage: A single-center experience

por Yi, Peng-Sheng, Liu, Jun-Ning, Li, Yong, Wu, Bin, Li, Jian-Shui
Publicado 2022

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a sy...

por Liu, Jun-Ning, Li, Ji-Jiang, Yan, Shu, Zhang, Guang-Nian, Yi, Peng-Sheng
Publicado 2023

Positive expression of ZNF689 indicates poor prognosis of hepatocellular carcinoma

por Yi, Peng Sheng, Wu, Bin, Deng, Da Wei, Zhang, Guang Nian, Li, Jian Shui
Publicado 2018

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic revi...

por Liu, Jun-Ning, Li, Ji-Jiang, Yan, Shu, Zhang, Guang-Nian, Yi, Peng-Sheng
Publicado 2023

miR‐203 inhibits augmented proliferation and metastasis of hepatocellular carcinoma residual in the promoted regenerating liver

por Zheng, Xiao‐Bo, Chen, Xiao‐Bo, Xu, Liang‐Liang, Zhang, Ming, Feng, Lei, Yi, Peng‐Sheng, Tang, Jian‐Wei, Xu, Ming‐Qing
Publicado 2017